ZNF473

Summary

ZNF473 (zinc finger protein 473, HGNC:23239) is a protein-coding gene on chromosome 19q13.33, encoding Zinc finger protein 473 (Q8WTR7). Involved in histone 3’-end pre-mRNA processing by associating with U7 snRNP and interacting with SLBP/pre-mRNA complex.

This gene encodes a member of the Krueppel C2H2-type zinc-finger family of proteins. The encoded protein, a component of the U7 snRNP complex, plays a role in histone 3’-end pre-mRNA processing and may be required for cell cycle progression to S phase. Expression level and methylation status of this gene may be correlated with bone mineral density.

Source: NCBI Gene 25888 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 130 total
• MANE Select transcript: NM_015428

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23239
Approved symbol	ZNF473
Name	zinc finger protein 473
Location	19q13.33
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1141, DKFZP434N043, HZFP100
Ensembl gene	ENSG00000142528
Ensembl biotype	protein_coding
OMIM	617908
Entrez	25888

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000270617, ENST00000391821, ENST00000445728, ENST00000594968, ENST00000595661, ENST00000598802, ENST00000598809, ENST00000599155, ENST00000601364, ENST00000892789

RefSeq mRNA: 3 — MANE Select: NM_015428 NM_001006656, NM_001308424, NM_015428

CCDS: CCDS33077, CCDS77335

Canonical transcript exons

ENST00000270617 — 5 exons

Exon	Start	End
ENSE00003052706	50026005	50026122
ENSE00003692393	50041730	50041819
ENSE00003892358	50039161	50039287
ENSE00003895320	50030892	50031091
ENSE00003895707	50044670	50048776

Expression profiles

Bgee: expression breadth ubiquitous, 212 present calls, max score 97.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.8294 / max 130.8146, expressed in 1711 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177119	8.0189	1694
177122	0.3776	130
177120	0.3273	166
177118	0.0599	22
177121	0.0458	11

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	97.56	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.34	gold quality
right testis	UBERON:0004534	88.96	gold quality
left testis	UBERON:0004533	88.94	gold quality
testis	UBERON:0000473	88.48	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	87.32	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.32	gold quality
triceps brachii	UBERON:0001509	84.93	gold quality
gluteal muscle	UBERON:0002000	84.45	gold quality
sperm	CL:0000019	84.08	gold quality
male germ cell	CL:0000015	84.05	gold quality
tongue squamous epithelium	UBERON:0006919	80.83	gold quality
adenohypophysis	UBERON:0002196	80.74	gold quality
parotid gland	UBERON:0001831	80.22	gold quality
pituitary gland	UBERON:0000007	80.11	gold quality
adult organism	UBERON:0007023	79.93	gold quality
ventricular zone	UBERON:0003053	79.92	gold quality
cortical plate	UBERON:0005343	79.64	gold quality
islet of Langerhans	UBERON:0000006	78.91	gold quality
ganglionic eminence	UBERON:0004023	78.19	gold quality
caudate nucleus	UBERON:0001873	78.03	gold quality
nucleus accumbens	UBERON:0001882	78.03	gold quality
right lung	UBERON:0002167	77.62	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	77.41	gold quality
oocyte	CL:0000023	77.28	gold quality
left uterine tube	UBERON:0001303	77.04	gold quality
pancreatic ductal cell	CL:0002079	76.98	silver quality
stromal cell of endometrium	CL:0002255	76.39	gold quality
granulocyte	CL:0000094	76.26	gold quality
putamen	UBERON:0001874	76.09	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.14
E-GEOD-124858	no	123.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

75 targeting ZNF473, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-7162-3P	99.89	68.16	1682
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-1825	99.72	68.11	1089

Literature-anchored findings (GeneRIF, showing 1)

• ZFP100 is the limiting factor for histone pre-mRNA processing in vivo. (PMID:16914750)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zgc:66472	ENSDARG00000075916
mus_musculus	Zfp473	ENSMUSG00000048012
rattus_norvegicus	Zfp473	ENSRNOG00000026572
drosophila_melanogaster	mld	FBGN0263490

Paralogs (36): ZNF302 (ENSG00000089335), ZNF184 (ENSG00000096654), CTCF (ENSG00000102974), ZNF574 (ENSG00000105732), ZBTB24 (ENSG00000112365), ZNF142 (ENSG00000115568), CTCFL (ENSG00000124092), ZNF827 (ENSG00000151612), ZNF689 (ENSG00000156853), ZNF208 (ENSG00000160321), ZNF91 (ENSG00000167232), ZNF526 (ENSG00000167625), ZNF764 (ENSG00000169951), ZNF747 (ENSG00000169955), ZNF282 (ENSG00000170265), ZNF160 (ENSG00000170949), ZNF497 (ENSG00000174586), ZBTB34 (ENSG00000177125), ZNF771 (ENSG00000179965), ZNF48 (ENSG00000180035), ZNF594 (ENSG00000180626), ZBTB37 (ENSG00000185278), ZFP92 (ENSG00000189420), ZNF107 (ENSG00000196247), ZNF729 (ENSG00000196350), ZNF569 (ENSG00000196437), ZNF420 (ENSG00000197050), ZNF785 (ENSG00000197162), ZNF665 (ENSG00000197497), ZNF181 (ENSG00000197841), ZNF347 (ENSG00000197937), ZNF84 (ENSG00000198040), ZBTB48 (ENSG00000204859), ZNF845 (ENSG00000213799), ZNF99 (ENSG00000213973), ZNF688 (ENSG00000229809)

Protein

Protein identifiers

Zinc finger protein 473 — Q8WTR7 (reviewed: Q8WTR7)

Alternative names: Zinc finger protein 100 homolog

All UniProt accessions (6): Q8WTR7, F8WEC7, M0QZY7, M0R032, M0R123, M0R2N2

UniProt curated annotations — full annotation on UniProt →

Function. Involved in histone 3’-end pre-mRNA processing by associating with U7 snRNP and interacting with SLBP/pre-mRNA complex. Increases histone 3’-end pre-mRNA processing but has no effect on U7 snRNP levels, when overexpressed. Required for cell cycle progression from G1 to S phases.

Subunit / interactions. Interacts with the SLBP/pre-mRNA complex but not with SLBP alone. Interacts with LSM11 in a U7 snRNP-dependent manner.

Subcellular location. Nucleus.

Domain organisation. The C2H2-type zinc finger 2 to 6 are necessary and sufficient for discrete Cajal bodies localization. The C2H2-type zinc finger 5 to 10 are necessary and sufficient for interaction with LSM11. The C2H2-type zinc finger 2 to 8 are necessary for interaction with the SLBP/RNA complex in the histone pre-mRNAs. The C2H2-type zinc finger 2 to 10 confer activity in histone pre-mRNA processing.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (3): NP_001006657, NP_001295353, NP_056243* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (96 total): strand 27, zinc finger region 20, helix 18, turn 9, sequence variant 6, cross-link 5, region of interest 4, compositionally biased region 3, sequence conflict 2, chain 1, domain 1

Structure

Experimental structures (PDB)

15 structures.

PDB	Method	Resolution (Å)
2EMB	SOLUTION NMR
2EMC	SOLUTION NMR
2EME	SOLUTION NMR
2EOU	SOLUTION NMR
2EOX	SOLUTION NMR
2EOY	SOLUTION NMR
2EOZ	SOLUTION NMR
2YRH	SOLUTION NMR
2YRJ	SOLUTION NMR
2YSV	SOLUTION NMR
2YTD	SOLUTION NMR
2YTE	SOLUTION NMR
2YTT	SOLUTION NMR
2YU5	SOLUTION NMR
9AZI	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WTR7-F1	60.31	0.01

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 148, 419, 549, 558, 635

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-111367	SLBP independent Processing of Histone Pre-mRNAs
R-HSA-212436	Generic Transcription Pathway
R-HSA-73856	RNA Polymerase II Transcription Termination
R-HSA-77588	SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs

MSigDB gene sets: 130 (showing top): GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_MRNA_3_END_PROCESSING, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_HISTONE_MRNA_METABOLIC_PROCESS, FISCHER_DREAM_TARGETS, BROWNE_HCMV_INFECTION_10HR_UP, REACTOME_METABOLISM_OF_RNA, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, GOCC_CAJAL_BODY, GOCC_NUCLEAR_BODY, GOCC_RIBONUCLEOPROTEIN_GRANULE, XU_GH1_EXOGENOUS_TARGETS_DN, NUYTTEN_NIPP1_TARGETS_DN, GAZDA_DIAMOND_BLACKFAN_ANEMIA_ERYTHROID_DN

GO Biological Process (3): regulation of transcription by RNA polymerase II (GO:0006357), mRNA 3’-end processing by stem-loop binding and cleavage (GO:0006398), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), Cajal body (GO:0015030)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Processing of Capped Intronless Pre-mRNA	2
RNA Polymerase II Transcription	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
histone mRNA metabolic process	1
mRNA 3’-end processing	1
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
nuclear ribonucleoprotein granule	1

Protein interactions and networks

STRING

700 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF473	LSM11	P83369	877
ZNF473	SLBP	Q14493	854
ZNF473	LSM10	Q969L4	781
ZNF473	SYMPK	Q92797	686
ZNF473	SNRPD1	P13641	650
ZNF473	EDC3	Q96F86	540
ZNF473	SNRPF	P62306	511
ZNF473	OR4N5	Q8IXE1	450
ZNF473	CPSF2	Q9P2I0	445
ZNF473	CPSF3	Q9UKF6	435
ZNF473	ATXN2	Q99700	430
ZNF473	OR4K14	Q8NGD5	418
ZNF473	SDR39U1	Q9NRG7	414
ZNF473	OR5L1	Q8NGL2	414
ZNF473	DDX6	P26196	409

IntAct

79 interactions, top by confidence:

A	B	Type	Score
TRIM41	ZNF473	psi-mi:“MI:0915”(physical association)	0.740
ZNF473	TRIM41	psi-mi:“MI:0915”(physical association)	0.740
ZNF473	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-8	ZNF473	psi-mi:“MI:0915”(physical association)	0.720
ZNF792	ZNF473	psi-mi:“MI:0915”(physical association)	0.670
AEN	ZNF473	psi-mi:“MI:0915”(physical association)	0.670
GPATCH2L	ZNF473	psi-mi:“MI:0915”(physical association)	0.670
ZNF473	AEN	psi-mi:“MI:0915”(physical association)	0.670
ZNF473	ZNF792	psi-mi:“MI:0915”(physical association)	0.670
ZNF473	rnps1	psi-mi:“MI:0915”(physical association)	0.560
ZSCAN12	ZNF473	psi-mi:“MI:0915”(physical association)	0.560
ZNF473	ZNF250	psi-mi:“MI:0915”(physical association)	0.560
CLK2	ZNF473	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-9	ZNF473	psi-mi:“MI:0915”(physical association)	0.560
DHX57	ZNF473	psi-mi:“MI:0915”(physical association)	0.560
rnps1	ZNF473	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (32): ZNF473 (Two-hybrid), ZNF473 (Two-hybrid), ZNF473 (Two-hybrid), GPATCH2L (Two-hybrid), ZNF250 (Two-hybrid), AEN (Two-hybrid), DHX57 (Two-hybrid), ZNF792 (Two-hybrid), KRTAP10-9 (Two-hybrid), KRTAP10-8 (Two-hybrid), TRIM41 (Two-hybrid), ZNF473 (Two-hybrid), ZNF473 (Two-hybrid), ZNF473 (Two-hybrid), ZNF473 (Two-hybrid)

ESM2 similar proteins: A1L1L7, A3KN36, D3ZVT0, O43296, P08042, P13682, P16373, P17023, P17097, P52738, P85977, Q02975, Q12901, Q14590, Q14592, Q2M3W8, Q2VY69, Q4V8A8, Q571J5, Q5CZA5, Q5R7I8, Q5RB33, Q5RBX0, Q61751, Q61967, Q6GQR8, Q6PF04, Q6ZNG0, Q6ZS27, Q86Y25, Q8BFS8, Q8BQC8, Q8IZ26, Q8N782, Q8N9Z0, Q8R1D1, Q8TF47, Q8WTR7, Q96LW1, Q9BS31

Diamond homologs: A0A9P4XV22, A1L1L7, A1YEQ3, A1YFW6, A2T6W2, B2KFW1, P08045, P17097, P18713, P18715, P18720, P18725, P18726, P18735, P18736, P18737, P18738, P18741, P18742, P18743, P18753, P18853, P21506, P51815, Q15072, Q28151, Q3KP31, Q5RBX0, Q5RBY9, Q5RFP4, Q6A085, Q6P1L6, Q6P9G9, Q7TNU6, Q8BGV5, Q8CF60, Q8R1D1, Q8WTR7, Q9BSG1, Q9UEG4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

130 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	105
Likely benign	20
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

926 predictions. Top by Δscore:

Variant	Effect	Δscore
19:50026026:G:GT	donor_gain	1.0000
19:50039159:A:AG	acceptor_gain	1.0000
19:50039159:AG:A	acceptor_gain	1.0000
19:50039159:AGGA:A	acceptor_loss	1.0000
19:50039160:G:GA	acceptor_gain	1.0000
19:50039160:G:GC	acceptor_loss	1.0000
19:50039160:GG:G	acceptor_gain	1.0000
19:50039160:GGA:G	acceptor_gain	1.0000
19:50039160:GGAA:G	acceptor_gain	1.0000
19:50039160:GGAAT:G	acceptor_gain	1.0000
19:50039283:GCTGG:G	donor_gain	1.0000
19:50039284:CTGG:C	donor_gain	1.0000
19:50039285:TGG:T	donor_gain	1.0000
19:50039286:GG:G	donor_gain	1.0000
19:50039286:GGG:G	donor_gain	1.0000
19:50039287:GG:G	donor_gain	1.0000
19:50039288:G:GG	donor_gain	1.0000
19:50039288:GTGA:G	donor_loss	1.0000
19:50039289:T:G	donor_loss	1.0000
19:50041725:TGCA:T	acceptor_loss	1.0000
19:50041727:CA:C	acceptor_loss	1.0000
19:50041728:A:AG	acceptor_gain	1.0000
19:50041729:G:A	acceptor_loss	1.0000
19:50041729:G:GG	acceptor_gain	1.0000
19:50041729:GA:G	acceptor_gain	1.0000
19:50041729:GAC:G	acceptor_gain	1.0000
19:50041729:GACC:G	acceptor_gain	1.0000
19:50041729:GACCC:G	acceptor_gain	1.0000
19:50041817:CTGG:C	donor_loss	1.0000
19:50041818:TGG:T	donor_loss	1.0000

AlphaMissense

5872 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:50046658:T:C	F739L	0.998
19:50046660:C:A	F739L	0.998
19:50046660:C:G	F739L	0.998
19:50046742:T:C	F767L	0.998
19:50046744:C:A	F767L	0.998
19:50046744:C:G	F767L	0.998
19:50046826:T:C	F795L	0.998
19:50046828:T:A	F795L	0.998
19:50046828:T:G	F795L	0.998
19:50046910:T:C	F823L	0.998
19:50046912:T:A	F823L	0.998
19:50046912:T:G	F823L	0.998
19:50046769:C:G	H776D	0.996
19:50046827:T:C	F795S	0.996
19:50046574:T:C	F711L	0.995
19:50046576:C:A	F711L	0.995
19:50046576:C:G	F711L	0.995
19:50046685:C:G	H748D	0.995
19:50046721:T:C	C760R	0.995
19:50046743:T:C	F767S	0.995
19:50046845:T:C	L801P	0.995
19:50046853:C:G	H804D	0.995
19:50046855:C:A	H804Q	0.995
19:50046855:C:G	H804Q	0.995
19:50046994:T:C	F851L	0.995
19:50046996:T:A	F851L	0.995
19:50046996:T:G	F851L	0.995
19:50046490:T:C	F683L	0.994
19:50046492:C:A	F683L	0.994
19:50046492:C:G	F683L	0.994

dbSNP variants (sampled 300 via entrez): RS1000043122 (19:50033269 C>G), RS1000075776 (19:50033503 A>G), RS1000214111 (19:50045459 A>T), RS1000298521 (19:50040793 C>A), RS1000470180 (19:50034827 G>A,T), RS1000600709 (19:50028921 A>G), RS1000697402 (19:50044114 G>C), RS1000811591 (19:50043713 G>A,T), RS1000860091 (19:50038070 G>A,C,T), RS1001034726 (19:50029123 G>A,T), RS1001078502 (19:50032205 G>A), RS1001229697 (19:50039533 A>G), RS1001332018 (19:50037836 G>C), RS1001393525 (19:50032622 C>T), RS1001434223 (19:50038601 C>T)

Disease associations

OMIM: gene MIM:617908 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

51 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, affects cotreatment, increases abundance	2
Acetaminophen	increases expression	2
Valproic Acid	increases methylation, decreases expression, increases expression	2
Cyclosporine	increases expression	2
Aflatoxin B1	increases expression, increases methylation	2
aristolochic acid I	increases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
beta-lapachone	increases expression	1
cobaltous chloride	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
potassium chromate(VI)	affects cotreatment, increases expression	1
ferrous chloride	decreases expression	1
cupric oxide	increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, increases expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	increases expression	1
abrine	increases expression	1
eprenetapopt	affects expression, affects reaction	1
licochalcone B	increases expression	1
bisphenol S	affects cotreatment, increases expression	1
NSC 689534	affects binding, increases expression	1
PCI 5002	increases expression, affects cotreatment	1
excavatolide B	increases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_XW49	HEK293 eGFP-ZNF473	Transformed cell line	Female

Clinical trials (associated diseases)

11 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03414970	PHASE3	ACTIVE_NOT_RECRUITING	Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT00461344	PHASE2	TERMINATED	Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer
NCT07499999	PHASE2	NOT_YET_RECRUITING	Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer
NCT00637364	PHASE1/PHASE2	SUSPENDED	High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain
NCT02779855	PHASE1/PHASE2	COMPLETED	Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01753908	EARLY_PHASE1	COMPLETED	Broccoli Sprout Extract in Treating Patients With Breast Cancer
NCT01796041	EARLY_PHASE1	COMPLETED	Intraoperative Imaging of Breast Cancer With Indocyanine Green
NCT01208974	Not specified	ACTIVE_NOT_RECRUITING	Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01875198	Not specified	TERMINATED	Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer
NCT03543397	Not specified	UNKNOWN	MRI in Ductal Carcinoma in Situ (DCIS)
NCT03834532	Not specified	COMPLETED	Living Well After Breast Surgery